A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Centocor Ortho Biotech

Status and phase: Completed; Phase 2

Conditions: Crohn's Disease

Treatments: Drug: Ustekinumab 3 mg/kg (IP); Drug: Ustekinumab 6 mg/kg (IP); Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP); Drug: Ustekinumab 1mg/kg (IP); Drug: Ustekinumab IV - Responder - Placebo SC (MP); Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP); Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Drug: Placebo IV - Responder - Placebo SC (MP); Drug: Placebo (IP)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00771667

C0743T26 (Other Identifier)

CR015238

Details and patient eligibility

About

A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of Crohn's disease.

Full description

In Crohn's disease there is inflammation (changes in body tissue which normally happen during injury or infection) and or ulceration (open sores) in the intestines.This occurs because the immune system (the part of the body that fights off infection) has an abnormal and overactive response against the intestine and bowel tissues of the body. Crohn's disease is usually treated with medications that either directly decrease inflammation or decrease the general activity of the immune system to improve the diarrhea, abdominal pain, and other symptoms of Crohn's Disease. Ustekinumab antibodies (natural substances made by your immune system to stick to and help remove foreign materials in your body that cause diseases) have been created to stick to and block the activity of two of the immune substances thought to cause abnormal inflammation of Crohn's disease. Patients who are eligible and who have received Remicade, Humira, or Cimzia and failed or been intolerant to one of these drugs will be randomized to either active drug (ustekinumab) or placebo. All patients will be randomized (like flipping a coin) at week 0 to be in one of 4 groups. At week 0 the study drug will be given by IV administration and at weeks 8 and 16 by subcutaneous injection. There will be 11 study visits in total and the study will continue until week 36. Blood and stool samples will be collected and studied, questionnaires to check on how you are doing in terms of your disease will be completed, an Electrocardiogram (EKG) obtained, safety evaluations conducted and diary cards distributed to be completed during the entire study. One of 4 groups: Grp 1-placebo, Grp 2-active drug 1mg/kg IV, Grp 3-active drug 3mg/kg IV, Grp 4-active drug 6mg/kg IV. Based on the clinical response status at Week 6, patients from Grps 2, 3 and 4 will be re-randomized at week 8 to receive either placebo or 90 mg SC at both weeks 8 and 16 and patients from Grp 1 will receive placebo at Week 8 and Week 16 or a 270 mg SC injection at Week 8 and 90 mg SC at Week 16.

Enrollment: 526 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have Crohn's disease or fistulizing Crohn's disease of at least 3 months duration
• Must have received Remicade, adalimumab or Cimzia at a dose approved for the treatment of Crohn's disease
• Must have failed or been intolerant to Remicade, Humira or Cimzia for treatment of Crohn's disease
• Must be 18 years of age or older
• Must have active Crohn's disease according to the Crohn's Disease Activity Index (CDAI > =220 and < =450).

Exclusion criteria

• Patients who have had any kind of bowel resection, diversions or placement of a stoma within 6 months
• Are pregnant, nursing or planning pregnancy (both men and women) while enrolled in the study or within 1 year after receiving study agent
• Patients who have received Remicade, Humira or Cimzia < =8 weeks before the first administration of study drug
• Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug
• Patients with a history of or ongoing chronic or recurrent infectious disease.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

526 participants in 10 patient groups, including a placebo group

Placebo (IP)

Placebo Comparator group

Treatment:

Drug: Placebo (IP)

Ustekinumab 1mg/kg (IP)

Experimental group

Treatment:

Drug: Ustekinumab 1mg/kg (IP)

Ustekinumab 3 mg/kg (IP)

Experimental group

Treatment:

Drug: Ustekinumab 3 mg/kg (IP)

Ustekinumab 6 mg/kg (IP)

Experimental group

Treatment:

Drug: Ustekinumab 6 mg/kg (IP)

Placebo IV - Responder - Placebo SC (MP)

Placebo Comparator group

Treatment:

Drug: Placebo IV - Responder - Placebo SC (MP)

Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC

Placebo Comparator group

Treatment:

Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)

Ustekinumab IV - Responder - Placebo SC (MP)

Placebo Comparator group

Treatment:

Drug: Ustekinumab IV - Responder - Placebo SC (MP)

Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)

Experimental group

Treatment:

Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)

Ustekinumab IV - Nonresponder - Placebo SC (MP)

Placebo Comparator group

Treatment:

Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP)

Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)

Experimental group

Treatment:

Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)